全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Stability-Indicating Validated Novel RP-HPLC Method for Simultaneous Estimation of Methylparaben, Ketoconazole, and Mometasone Furoate in Topical Pharmaceutical Dosage Formulation

DOI: 10.1155/2013/342794

Full-Text   Cite this paper   Add to My Lib

Abstract:

A simple, specific, precise, and accurate RP-HPLC method has been developed and validated for simultaneous estimation of Methylparaben (MP), Ketoconazole (KT), and Mometasone Furoate (MF) topical pharmaceutical dosage formulation. The separation was achieved by Waters X Terra C18 column using mobile phase consisting of buffer (triethyl amine in water, pH adjusted to 6.5 with glacial acetic acid)-acetonitrile (40?:?60,?v/v) at a flow rate of 1.5?mL/min and detection at 250?nm. The method showed linearity with correlation coefficient <0.9999 over the range of 0.12–15.2?μg/mL, 0.67–149.4?μg/mL, and 0.42–7.6?μg/mL for MP, KT, and MF, respectively. The mean recoveries were found to be in the range of 99.9–101.1% for all the components. The method was validated as per the ICH guidelines for linearity, limit of detection, limit of quantification, accuracy, precision, robustness and solution stability. Stability indicating capability of the developed method was established by analyzing forced degradation of samples in which spectral purity of MP, KT, and MF along with separation of degradation products from analytes peak was achieved. The method can be successfully applied for routine analysis of quantitative determination of MP, KT, and MF in pharmaceutical dosage form. 1. Introduction Mometasone Furoate (MF), (11β, 16α)-9, 21-dichloro-11-hydroxy-16-methyl-3, 20-dioxopregna-1, 4-dien-17-yl 2-furoate (Figure 1(a)) is a topical corticosteroid; it has anti-inflammatory, antipruritic, and vasoonstrictive properties. Mometasone inhibits the action of allergic reactions, eczema, and psoriasis that cause inflammation, redness, and swelling [1, 2]. Ketoconazole (KT), an imidazole derivative, chemically 1-[4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]ethan-1-one (Figure 1(b)) is an antifungal agent with topical and systemic action and can be incorporated into several pharmaceutical forms. As for example a ketoconazole shampoo is effective against seborrhoeic dermatitis as well as Pityriasis versicolor [3–7]. KT and MF in combined dosage form are used in the treatment of mild to moderate inflamed cutaneous mycoses with antimycotic activity. Figure 1: Chemical structure of (a) Mometasone Furoate, (b) Ketoconazole, and (c) Methylparaben. The preservative system is an important part of semisolid formulations in preventing the deterioration of formulations from microbial contamination. Methylparaben (MP) (Figure 1(c)) and its salts are most commonly used as preservatives for many years. To establish their

References

[1]  K. Srinivasarao, V. Gorule, R. C. Venkata, and K. A. Venkata, “A validated method development for estimation of formoterol fumarate and mometasone furoate in metered dose inhalation form HPLC,” Journal of Analytical Bioanalytical Techniques, vol. 3, no. 7, pp. 1–4, 2012.
[2]  S. Shaikh, M. S. Muneera, O. A. Thusleem, M. Tahir, and A. V. Kondaguli, “A simple RP-HPLC method for the simultaneous quantitation of chlorocresol, mometasone furoate, and fusidic acid in creams,” Journal of Chromatographic Science, vol. 47, no. 2, pp. 178–183, 2009.
[3]  http://en.wikipedia.org/wiki/Ketoconazole.
[4]  I. Staub and A. M. Bergold, “Determination of ketoconazole in shampoo by high performance liquid chromatography,” Acta Farmaceutica Bonaerense, vol. 23, no. 3, pp. 387–390, 2004.
[5]  R. U. Peter and U. Richarz-Barthauer, “Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial,” British Journal of Dermatology, vol. 132, no. 3, pp. 441–445, 1995.
[6]  C. Piérard-Franchimont, G. E. Piérard, J. E. Arrese, and P. de Doncker, “Effect of ketoconazole 1% and 2% shampoos on severe dandruff and seborrhoeic dermatitis: clinical, squamometric and mycological assessments,” Dermatology, vol. 202, no. 2, pp. 171–176, 2001.
[7]  R. Giordani, J. Trebaux, M. Masi, and P. Regli, “Enhanced antifungal activity of ketoconazole by Euphorbia characias latex against Candida albicans,” Journal of Ethnopharmacology, vol. 78, no. 1, pp. 1–5, 2001.
[8]  J. Boonleang and C. Tanthana, “Simultaneous stability-indicating hplc method for the determination of cisapride, methylparaben and propylparaben in oral suspension,” Songklanakarin Journal of Science and Technology, vol. 32, no. 4, pp. 379–385, 2010.
[9]  European Medicines Agency, “Guideline on excipients in the dossier for application for marketing authorisation of a medicinal product,” Doc. Ref. EMEA/CHMP/QWP/396951/ 2006, London, UK, 2006.
[10]  ICH Q6A, “Specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances,” in International Conference on Harmonization, 1999.
[11]  X. W. Teng, K. Foe, K. F. Brown, D. J. Cutler, and N. M. Davies, “High-performance liquid chromatographic analysis of mometasone furoate and its degradation products: application to in vitro degradation studies,” Journal of Pharmaceutical and Biomedical Analysis, vol. 26, no. 2, pp. 313–319, 2001.
[12]  J. Zhu and C. Coscolluella, “Chromatographic assay of pharmaceutical compounds under column overloading,” Journal of Chromatography B, vol. 741, no. 1, pp. 55–65, 2000.
[13]  J. C. H. Donovan and J. G. DeKoven, “Cross-reactions to desoximetasone and mometasone furoate in a patient with multiple topical corticosteroid allergies,” Dermatitis, vol. 17, no. 3, pp. 147–151, 2006.
[14]  H. C. Korting, K. Maslen, G. Gross, and C. Willers, “Comparison of activity of different topical corticosteroid creams and ointments using a vasoconstriction assay: superiority of hydrocortisone butyrate over hydrocortisone,” Journal of the German Society of Dermatology, vol. 3, no. 5, pp. 348–353, 2005.
[15]  K. A. Shaikh and A. T. Patil, “Stability-indicating HPLC method for the determination of mometasone furoate, oxymetazoline, phenyl ethanol and benzalkonium chloride in nasal spray solution,” Journal of Trace Analysis in Food and Drugs, vol. 1, pp. 14–21, 2013.
[16]  USP 29 NF 24, United States Pharmacopoeia, U.S. Pharmacopeial Convention, Rockville, MD, USA, 2006.
[17]  The United States Pharmacopoeia, 32th NF 27, Ketoconazole, United States Pharmacopeial Convention, Rockwille, MD, USA, pp.2737–2738, 2009.
[18]  European Pharmacopoeia, Ketoconazole 01/2008:0921 corrected 6.0, European Pharmacopoeia Commission, 6th edition, 2008.
[19]  E. R. M. Kedor-Hackmann, M. M. F. Nery, and M. I. R. M. Santoro, “Determination of ketoconazole in pharmaceutical preparations by ultraviolet spectrophotometry and HPLC,” Analytical Letters, vol. 27, no. 2, pp. 363–376, 1994.
[20]  A. Kumar, P. Srinivas, K. Spandana, N. Rama, and J. VidyaSagar, “Rapid and sensitive HPLC method for the determination of sirolimus with ketoconazole as internal standard and its further applications,” International Journal of Pharmaceutical Sciences Drug Research, vol. 4, no. 1, pp. 70–73, 2012.
[21]  R. K. Jat, S. Sharma, R. C. Chhipa, R. Singh, and I. Alam, “Development and validation of RP-HPLC method for estimation of ketoconazole in bulk drug,” Pharmacophore, vol. 3, no. 2, pp. 123–129, 2012.
[22]  V. K. Venishetty, N. Parikh, R. Sistla, F. J. Ahmed, and P. V. Diwan, “Application of validated RP-HPLC method for simultaneous determination of docetaxel and ketoconazole in solid lipid nanoparticles,” Journal of Chromatographic Science, vol. 49, no. 2, pp. 136–141, 2011.
[23]  R. A. Mhaske and S. Sahasrabudhe, “Identification of major degradation products of Ketoconazole,” Scientia Pharmaceutica, vol. 79, no. 4, pp. 817–836, 2011.
[24]  Y. V. Heyden, A. N. M. Nguyet, M. R. Detaevernier, D. L. Massart, and J. Plaizier-Vercammen, “Simultaneous determination of ketoconazole and formaldehyde in a shampoo: liquid chromatography method development and validation,” Journal of Chromatography A, vol. 958, no. 1-2, pp. 191–201, 2002.
[25]  A. N. M. Nguyet, L. Tallieu, J. Plaizier-Vercammen, D. L. Massart, and Y. V. Heyden, “Validation of an HPLC method on short columns to assay ketoconazole and formaldehyde in shampoo,” Journal of Pharmaceutical and Biomedical Analysis, vol. 32, no. 1, pp. 1–19, 2003.
[26]  E. M. Abdel-Moety, F. I. Khattab, K. M. Kelani, and A. M. AbouAl-Alamein, “Chromatographic determination of clotrimazole, ketoconazole and fluconazole in pharmaceutical formulations,” Farmaco, vol. 57, no. 11, pp. 931–938, 2002.
[27]  M. V. Vertzoni, C. Reppas, and H. A. Archontaki, “Optimization and validation of a high-performance liquid chromatographic method with UV detection for the determination of ketoconazole in canine plasma,” Journal of Chromatography B, vol. 839, no. 1-2, pp. 62–67, 2006.
[28]  K. H. Yuen and K. K. Peh, “Simple high-performance liquid chromatographic method for determination of ketoconazole in human plasma,” Journal of Chromatography B, vol. 715, no. 2, pp. 436–440, 1998.
[29]  S. Bajad, R. K. Johri, K. Singh, J. Singh, and K. L. Bedi, “Simple high-performance liquid chromatography method for the simultaneous determination of ketoconazole and piperine in rat plasma and hepatocyte culture,” Journal of Chromatography A, vol. 949, no. 1-2, pp. 43–47, 2002.
[30]  D. A. Hamdy and D. R. Brocks, “A stereospecific high-performance liquid chromatographic assay for the determination of ketoconazole enantiomers in rat plasma,” Biomedical Chromatography, vol. 22, no. 5, pp. 542–547, 2008.
[31]  P. de Bruijn, D. F. S. Kehrer, J. Verweij, and A. Sparreboom, “Liquid chromatographic determination of ketoconazole, a potent inhibitor of CYP3A4-mediated metabolism,” Journal of Chromatography B, vol. 753, no. 2, pp. 395–400, 2001.
[32]  I. Staub, L. Flores, G. Gosmann et al., “Photostability studies of ketoconazole: isolation and structural elucidation of the main photodegradation products,” Latin American Journal of Pharmacy, vol. 29, no. 7, pp. 1100–1106, 2010.
[33]  B. Gjorgjeska, “Determination of ketoconazole in tablets by using three different methods,” European Medical, Health and Pharmaceutical Journal, vol. 4, p. 8, 2012.
[34]  P. Arranz, A. Arranz, J. M. Moreda, A. Cid, and J. F. Arranz, “Stripping voltammetric and polarographic techniques for the determination of anti-fungal ketoconazole on the mercury electrode,” Journal of Pharmaceutical and Biomedical Analysis, vol. 33, no. 4, pp. 589–596, 2003.
[35]  Q. Huang, G.-J. Wang, J.-G. Sun, X.-L. Hu, Y.-H. Lu, and Q. Zhang, “Simultaneous determination of docetaxel and ketoconazole in rat plasma by liquid chromatography/electrospray ionization tandem mass spectrometry,” Rapid Communications in Mass Spectrometry, vol. 21, no. 6, pp. 1009–1018, 2007.
[36]  G. Chen, B. N. Pramanik, Y.-H. Liu, and U. A. Mirza, “Applications of LC/MS in structure identifications of small molecules and proteins in drug discovery,” Journal of Mass Spectrometry, vol. 42, no. 3, pp. 279–287, 2007.
[37]  S. Sahasranaman, Y. Tang, D. Biniasz, and G. Hochhaus, “A sensitive liquid chromatography-tandem mass spectrometry method for the quantification of mometasone furoate in human plasma,” Journal of Chromatography B, vol. 819, no. 1, pp. 175–179, 2005.
[38]  Y.-L. Chen, L. Felder, X. Jiang, and W. Naidong, “Determination of ketoconazole in human plasma by high-performance liquid chromatography-tandem mass spectrometry,” Journal of Chromatography B, vol. 774, no. 1, pp. 67–78, 2002.
[39]  I. Velikinac, O. ?udina, I. Jankovi?, D. Agbaba, and S. Vladimirov, “Comparison of capillary zone electrophoresis and high performance liquid chromatography methods for quantitative determination of ketoconazole in drug formulations,” Farmaco, vol. 59, no. 5, pp. 419–424, 2004.
[40]  K.-L. Kuo and Y.-Z. Hsieh, “Determination of preservatives in food products by cyclodextrin-modified capillary electrophoresis with multiwavelength detection,” Journal of Chromatography A, vol. 768, no. 2, pp. 334–341, 1997.
[41]  J. L. Bernal, M. J. del Nozal, L. Toribio, M. I. Montequi, and E. M. Nieto, “Separation of ketoconazole enantiomers by chiral subcritical-fluid chromatography,” Journal of Biochemical and Biophysical Methods, vol. 43, no. 1–3, pp. 241–250, 2000.
[42]  K. Farhadi and R. Maleki, “New spectrophotometric method for the determination of ketoconazole based on the oxidation reactions,” Analytical Sciences, vol. 17, pp. 867–870, 2001.
[43]  E. R. M. Kedor-Hackmann, M. I. R. M. Santoro, A. K. Singh, and A. C. Peraro, “First-derivative ultraviolet spectrophotometric and high performance liquid chromatographic determination of ketoconazole in pharmaceutical emulsions,” Brazilian Journal of Pharmaceutical Sciences, vol. 42, no. 1, pp. 91–98, 2006.
[44]  M. M. Ayad, M. M. EL-Henawee, H. E. Abdellatef, and H. M. EL Sayed, “Spectrophotometric determination of levonorgestrel, norethisterone acetate, mometasone furoate and fluticasone propionate using 4-amino-antipyrine,” Cairo Bull, vol. 43, no. 3, 2005.
[45]  A. Kulkarni, N. Rabindra, and N. Ranjane, “Simultaneous estimation of Nadifloxacin and Mometasone Furoate in topical cream by HPTLC method,” Der Pharma Chemica, vol. 2, no. 3, pp. 25–30, 2010.
[46]  “Stability testing of new drug substances and products, Q1A (R2),” in International Conference on Harmonization (ICH '03), IFPMA, Geneva, Switzerland, 2003.
[47]  ICH, Validation of Analytical Procedure, Text and Methodology Q2 (R1), IFPMA, Geneva, Switzerland, 2005.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133